Please use this identifier to cite or link to this item: https://doi.org/10.1136/bmjgast-2020-000452
DC FieldValue
dc.titleProfiling of gastric cancer cell-surface markers to achieve tumour-normal discrimination
dc.contributor.authorToh, J.
dc.contributor.authorHoppe, M.M.
dc.contributor.authorThakur, T.
dc.contributor.authorYang, H.
dc.contributor.authorTan, K.T.
dc.contributor.authorPang, B.
dc.contributor.authorHo, S.
dc.contributor.authorRoy, R.
dc.contributor.authorHo, K.Y.
dc.contributor.authorYeoh, K.G.
dc.contributor.authorTan, P.
dc.contributor.authorSundar, R.
dc.contributor.authorJeyasekharan, A.
dc.date.accessioned2021-08-27T04:22:17Z
dc.date.available2021-08-27T04:22:17Z
dc.date.issued2020
dc.identifier.citationToh, J., Hoppe, M.M., Thakur, T., Yang, H., Tan, K.T., Pang, B., Ho, S., Roy, R., Ho, K.Y., Yeoh, K.G., Tan, P., Sundar, R., Jeyasekharan, A. (2020). Profiling of gastric cancer cell-surface markers to achieve tumour-normal discrimination. BMJ Open Gastroenterology 7 (1) : e000452. ScholarBank@NUS Repository. https://doi.org/10.1136/bmjgast-2020-000452
dc.identifier.issn2054-4774
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/199753
dc.description.abstractBackground Differentiating between malignant and normal cells within tissue samples is vital for molecular profiling of cancer using advances in genomics and transcriptomics. Cell-surface markers of tumour-normal discrimination have additional value in terms of translatability to diagnostic and therapeutic strategies. In gastric cancer (GC), previous studies have identified individual genes or proteins that are upregulated in cancer. However, a systematic analysis of cell-surface markers and development of a composite panel involving multiple candidates to differentiate tumour from normal has not been previously reported. Methods Whole transcriptome sequencing (WTS) of GC and matched normal samples from the Singapore Gastric Cancer Consortium (SGCC) was used as a discovery cohort to identify upregulated putative cell-surface proteins. Matched WTS data from the The Cancer Genome Atlas (TCGA) was used as a validation cohort. Promising candidates from this analysis were validated orthogonally using multispectral immunohistochemistry (mIHC) with automated quantitative analysis using the Vectra platform. mIHC was performed on a tissue microarray containing matched normal, marginal and tumour tissues. The receiver-operating characteristic (ROC) curves were analysed to identify markers with the highest diagnostic validity independently and in combination. Results Analysis of putative membrane protein transcripts from the SGCC discovery cohort WTS data (n=15 matched tumour and normal pairs) identified several differentially and highly expressed candidates in tumour compared with normal tissues. After validation with TCGA data (n=29 matched tumour and normal pairs), the following proteins were selected for mIHC analysis: CEACAM5, CEACAM6, CLDN4, CLDN7, and EpCAM. These were compared with established glycoprotein markers in GC, namely CA19-9 and CA72-4. Individual ROC curves yielded the best performance for CEACAM5 (area under the ROC curve (AUC)=0.80), CEACAM6 (AUC=0.82), EpCAM (AUC=0.83), and CA72-4 (AUC=0.76). Combined multiplexed imaging of these four markers revealed improved specificity and sensitivity for detection of tumour from normal tissue (AUC of 4-plex=0.91). Conclusion CEAMCAM5, CEACAM6, EpCAM, and CA72-4 form a versatile set of markers for robust discrimination of GC from adjacent normal tissue. As cell-surface markers, they are compatible with both IHC and live imaging approaches. These candidates may be exploited to improve automated identification of tumour tissue in GC. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
dc.publisherBMJ Publishing Group
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScopus OA2020
dc.subjectCancer genetics
dc.subjectDiagnostic and therapeutic endoscopy
dc.subjectGastric adenocarcinoma
dc.subjectGastric carcinoma
dc.subjectTumour markers
dc.typeArticle
dc.contributor.departmentCANCER SCIENCE INSTITUTE OF SINGAPORE
dc.contributor.departmentMEDICINE
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.description.doi10.1136/bmjgast-2020-000452
dc.description.sourcetitleBMJ Open Gastroenterology
dc.description.volume7
dc.description.issue1
dc.description.pagee000452
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1136_bmjgast_2020_000452.pdf1.16 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons